Researchers at the University of Nebraska Medical Center have devised a new ultrasound contrast agent which is safe and can reach the left side of the heart in adequate amounts to determine blood flow to the muscle of the heart. The contrast agent comprises a simple sonicated mixture of a protein the body normally makes (albumin) combined with a naturally occurring sugar (dextrose). This mixture upon sonication contains small bubbles (microbubbles) and can be used following an intravenous injection to study blood flow to the muscle of the heart (myocardium) without the need of invasive catheters or radiation.
This technology is useful for improving accuracy of diagnostic methods using ultrasonic imaging, while simultaneously reducing overall costs.
Features and Benefits
• Decrease risks to patient by eliminating use of radiation
• Non-invasive procedure
• Increased accuracy for improved diagnosis and therapeutic
US Patent Issued:
UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with the University of Nebraska Medical Center.
Technology Marketing and Licensing for The University of Nebraska Medical CenterView profile
Clients in focus...